India Halts Cough Syrup Production at Factory Linked to Deaths of Gambian Children

Anil Vij, the health minister of India’s northern state of Haryana, has ordered Maiden Pharmaceutical LimitedMaiden Pharmaceutical Limited to stop manufacturing all drugs with immediate effect.

This is said to have come into effect as WHO reports confirmed that India has halted all production at the main factory of Maiden Pharmaceuticals near New Delhi following the claim that its cough syrups exported to the Gambia may be linked to the deaths of manychildren there. India is said to be supplying 45% of all generic medicines to Africa.

The recent incident which has claimed the lives of over 69 children, according to WHO has come as a blow to the industry whose exports more than doubled in the last decade to hit $24.5 billion last fiscal year.

Indian authorities inspected the Maiden factory in the state of Haryana four times this month and suspended all manufacturing activities there on Tuesday “on grounds of deficiencies found in location inspection”.

Haryana’s health minister said an inspection conducted jointly by state and federal officials found 12 “flaws”.

READ MORE: Leadership role in economy to top discussion as foundation plans confab

“Keeping this in view, the entire production of the company has been banned and notice has also been issued,” minister Anil Vij said in a statement, referring to Maiden’s main factory in Sonipat district.

A top Indian health official, who declined to be named, said the government would not tolerate wrongdoing but that it was important to find out what exactly happened in the Gambia.

He denied allegations by some critics that health regulations in India, especially at the level of states, were lax.

The federal health ministry has formed a committee of four experts that will advise further action after “examining and analysing adverse event reports, causal relationship and all related details shared by the WHO”.


Please enter your comment!
Please enter your name here

eleven − seven =